Document is current
Any future updates will be listed below
-
Authors
Bustoros, Mark https://orcid.org/0000-0002-4652-5449
Anand, Shankara
Sklavenitis-Pistofidis, Romanos
Redd, Robert https://orcid.org/0000-0002-1329-5288
Boyle, Eileen M. https://orcid.org/0000-0001-8791-1744
Zhitomirsky, Benny
Dunford, Andrew J.
Tai, Yu-Tzu https://orcid.org/0000-0001-6199-3569
Chavda, Selina J.
Boehner, Cody
Neuse, Carl Jannes
Rahmat, Mahshid https://orcid.org/0000-0001-7100-463X
Dutta, Ankit https://orcid.org/0000-0003-2535-3729
Casneuf, Tineke
Verona, Raluca
Kastritis, Efstathis
Trippa, Lorenzo
Stewart, Chip
Walker, Brian A. https://orcid.org/0000-0002-8615-6254
Davies, Faith E.
Dimopoulos, Meletios-Athanasios https://orcid.org/0000-0001-8990-3254
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Yong, Kwee https://orcid.org/0000-0002-6487-276X
Morgan, Gareth J. https://orcid.org/0000-0002-4271-6360
Aguet, François https://orcid.org/0000-0001-9414-300X
Getz, Gad https://orcid.org/0000-0002-0936-0753
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
- License Information
-
More Information
Article History
Received: 6 May 2021
Accepted: 13 May 2022
First Online: 15 June 2022
Competing interests
: There was no commercial funding for this study. M.B. has consulting roles with Takeda and Epizyme and has received honoraria from Takeda, Janssen, and Bristol Myers Squibb (BMS). E.K. has received honoraria from Amgen, Janssen, Takeda, Genesis Pharma, GSK, Pfizer, and research support from Amgen, Janssen, and Pfizer. R.J.S. is on the Data and Safety Monitoring Board of Juno and Celgene; has consulting roles with Gilead, Merck, and Astellas; and is on the Board of Directors of Kiadis. M.A.D. has received honoraria from Amgen, Celgene, Janssen, and Takeda. T.C. is an employee of Janssen R&D and holds stock in Johnson & Johnson. G.J.M. reports consulting roles with BMS, Sanofi, Karyopharm, Janssen, Roche, and Genentech. F.D. is on advisory boards for Amgen, BMS, Celgene, GSK, Janssen, Oncopeptides, Sanofi, and Takeda. P.L.B. reports consulting roles with Novartis, Amgen, Pfizer, BMS. B.W. reports research funding from BMS and Genentech, and Honoraria from Sanofi. I.M.G. has a consulting or advisory role with AbbVie, Adaptive, Amgen, Aptitude Health, Bristol Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, The Binding Site, and Window Therapeutics; has received speaker fees from Vor Biopharma and Veeva Systems, Inc.; and her spouse is the CMO and equity holder of Disc Medicine. G.G. is a founder, consultant, and holds privately held equity in Scorpion Therapeutics, received research funding from IBM and Pharmacyclics, and is an inventor on patent applications related to ABSOLUTE, MSMuTect, MSMutSig (Title: COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH MICROSATELLITE INSTABILITY, serial number: 16/640,349), MSIdetect (Title: COMPOSITIONS AND METHODS FOR TUMOR CHARACTERIZATION, serial number: PCT/US2021/058241), POLYSOLVER (Title: Polymorphic Gene Typing and Somatic Change Detection Using Sequencing Data, serial number: 15/037,394). F.A. and G.G. are inventors of a patent application for scaling computational genomics using graphics processing units (Title: Methods of Scaling Computational Genomics with Specialized Architectures for Highly Parallelized Computations and Uses Thereof, serial number: 17/284,708).
